FI104323B1 - Menetelmä terapeuttisesti käyttökelpoisen 3-alkyyli-4-metyyli-4-(3-hydroksifenyyli)piperidiini-N-alkyylikarboksylaattien trans-3,4-isomeerien valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisen 3-alkyyli-4-metyyli-4-(3-hydroksifenyyli)piperidiini-N-alkyylikarboksylaattien trans-3,4-isomeerien valmistamiseksi

Info

Publication number
FI104323B1
FI104323B1 FI921345A FI921345A FI104323B1 FI 104323 B1 FI104323 B1 FI 104323B1 FI 921345 A FI921345 A FI 921345A FI 921345 A FI921345 A FI 921345A FI 104323 B1 FI104323 B1 FI 104323B1
Authority
FI
Finland
Prior art keywords
alkyl
piperidine
preparation
hydroxyphenyl
isomer
Prior art date
Application number
FI921345A
Other languages
English (en)
Swedish (sv)
Other versions
FI921345A0 (fi
FI921345A (fi
FI104323B (fi
Inventor
Buddy Eugene Cantrell
Dennis Michael Zimmerman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of FI921345A0 publication Critical patent/FI921345A0/fi
Publication of FI921345A publication Critical patent/FI921345A/fi
Application granted granted Critical
Publication of FI104323B1 publication Critical patent/FI104323B1/fi
Publication of FI104323B publication Critical patent/FI104323B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/42Oxygen atoms attached in position 3 or 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI921345A 1991-03-29 1992-03-27 Menetelmä terapeuttisesti käyttökelpoisen 3-alkyyli-4-metyyli-4-(3-hydroksifenyyli)piperidiini-N-alkyylikarboksylaattien trans-3,4-isomeerien valmistamiseksi FI104323B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67704291A 1991-03-29 1991-03-29
US67704291 1991-03-29

Publications (4)

Publication Number Publication Date
FI921345A0 FI921345A0 (fi) 1992-03-27
FI921345A FI921345A (fi) 1992-09-30
FI104323B1 true FI104323B1 (fi) 1999-12-31
FI104323B FI104323B (fi) 1999-12-31

Family

ID=24717068

Family Applications (1)

Application Number Title Priority Date Filing Date
FI921345A FI104323B (fi) 1991-03-29 1992-03-27 Menetelmä terapeuttisesti käyttökelpoisen 3-alkyyli-4-metyyli-4-(3-hydroksifenyyli)piperidiini-N-alkyylikarboksylaattien trans-3,4-isomeerien valmistamiseksi

Country Status (24)

Country Link
EP (1) EP0506478B1 (fi)
JP (1) JP3056321B2 (fi)
KR (1) KR100229117B1 (fi)
CN (1) CN1041309C (fi)
AT (1) ATE157653T1 (fi)
AU (1) AU644051B2 (fi)
BR (1) BR9201084A (fi)
CY (1) CY2062B1 (fi)
CZ (1) CZ284993B6 (fi)
DE (1) DE69221919T2 (fi)
DK (1) DK0506478T3 (fi)
ES (1) ES2106825T3 (fi)
FI (1) FI104323B (fi)
GR (1) GR3025494T3 (fi)
HK (1) HK1000441A1 (fi)
HU (2) HU221316B1 (fi)
IE (1) IE921003A1 (fi)
IL (1) IL101382A (fi)
MX (1) MX9201356A (fi)
NO (1) NO178398C (fi)
NZ (1) NZ242117A (fi)
RU (1) RU2076863C1 (fi)
YU (1) YU30492A (fi)
ZA (1) ZA922180B (fi)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434171A (en) * 1993-12-08 1995-07-18 Eli Lilly And Company Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates
GB9725114D0 (en) * 1997-11-28 1998-01-28 Pfizer Ltd Treatment of pruritus
GB9810671D0 (en) 1998-05-18 1998-07-15 Pfizer Ltd Anti-pruritic agents
TWI244481B (en) * 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912415D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912410D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912416D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912417D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
NZ520554A (en) * 2000-02-08 2005-08-26 Euro Celtique S Tamper-resistant oral opioid agonist formulations
IL161157A0 (en) 2001-10-22 2004-08-31 Pfizer Prod Inc 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
DE10161818A1 (de) * 2001-12-14 2003-06-26 Gruenenthal Gmbh Substituierte 1,5-Diaminopentan-3-ol-Verbindungen
CA2522323C (en) * 2003-04-14 2009-09-15 Pfizer Products Inc. 3-azabicyclo[3.2.1]octane derivatives as opioid receptor ligands
US6992090B2 (en) * 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
CA2563502A1 (en) 2004-04-09 2005-10-20 Chugai Seiyaku Kabushiki Kaisha Novel water-soluble prodrug
US7700626B2 (en) * 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
CN100383121C (zh) * 2006-03-07 2008-04-23 天津泰普药品科技发展有限公司 阿韦苄酯化合物及其制备方法和以该化合物制备阿韦莫哌的工艺
ATE516021T1 (de) 2006-04-21 2011-07-15 Dsm Ip Assets Bv Verwendung von opioid-rezeptor-antagonisten
CN101838233A (zh) * 2010-05-27 2010-09-22 北京万全阳光医学技术有限公司 一种阿维莫泮关键中间体的制备方法
CN101967118B (zh) * 2010-10-14 2013-01-30 成都苑东药业有限公司 爱维莫潘的制备方法
CN105820106B (zh) * 2015-01-07 2018-11-09 上海医药工业研究院 爱维莫潘中间体的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3884916A (en) * 1971-03-30 1975-05-20 Janssen Pharmaceutica Nv 2,2-Diaryl-4-(4-aryl-4-hydroxy-piperidino)-butyramides
US4115400A (en) * 1976-05-27 1978-09-19 Eli Lilly And Company 1-Azoniabicyclo[3.1.0]hexanes
NZ224236A (en) * 1987-04-16 1990-08-28 Lilly Co Eli Trans 3,4 pyridine derivatives and pharmaceutical compositions
FI97540C (fi) * 1989-11-06 1997-01-10 Sanofi Sa Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi

Also Published As

Publication number Publication date
DE69221919T2 (de) 1998-01-29
KR100229117B1 (ko) 1999-11-01
CZ284993B6 (cs) 1999-04-14
FI921345A0 (fi) 1992-03-27
FI921345A (fi) 1992-09-30
HU9201013D0 (en) 1992-06-29
HU221316B1 (en) 2002-09-28
YU30492A (sh) 1994-12-28
NO921182D0 (no) 1992-03-26
EP0506478B1 (en) 1997-09-03
EP0506478A1 (en) 1992-09-30
MX9201356A (es) 1992-10-01
NO178398C (no) 1996-03-20
DK0506478T3 (da) 1997-10-20
ATE157653T1 (de) 1997-09-15
AU644051B2 (en) 1993-12-02
BR9201084A (pt) 1992-11-24
NZ242117A (en) 1994-11-25
DE69221919D1 (de) 1997-10-09
IL101382A0 (en) 1992-11-15
CY2062B1 (en) 1998-06-12
CN1041309C (zh) 1998-12-23
ES2106825T3 (es) 1997-11-16
RU2076863C1 (ru) 1997-04-10
JP3056321B2 (ja) 2000-06-26
NO178398B (no) 1995-12-11
FI104323B (fi) 1999-12-31
GR3025494T3 (en) 1998-02-27
IL101382A (en) 1997-04-15
HK1000441A1 (en) 1998-03-20
NO921182L (no) 1992-09-30
CN1065455A (zh) 1992-10-21
ZA922180B (en) 1993-09-27
CS90292A3 (en) 1992-12-16
IE921003A1 (en) 1992-10-07
HU211622A9 (en) 1995-12-28
JPH0597806A (ja) 1993-04-20
HUT66596A (en) 1994-12-28
KR920018024A (ko) 1992-10-21
AU1388092A (en) 1992-10-01

Similar Documents

Publication Publication Date Title
FI104323B1 (fi) Menetelmä terapeuttisesti käyttökelpoisen 3-alkyyli-4-metyyli-4-(3-hydroksifenyyli)piperidiini-N-alkyylikarboksylaattien trans-3,4-isomeerien valmistamiseksi
DE69033308D1 (de) Decahydro-isochinolin-derivate
DE69427017D1 (de) Herstellung von 3,4,4-trisubstituiertem Piperidinyl-n-alkylcarboxylaten und Zwischenverbindungen, verwendbar als opioid Antagonisten
DE59207880D1 (de) 8-Vinyl- und 8-Ethinyl-chinoloncarbonsäuren
DE69030632D1 (de) Substituierte Chinolincarboxylsäure
FI960254A (fi) Menetelmä N-(4-hydroksifenyyli)-retiiniamidin valmistamiseksi
FI103727B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten 2-amino-4-substioitu-fenyyli-4H-pyrano[3,2-h]kinoliini-3-karbonitriilien valmistamiseksi
FI98459B (fi) Menetelmä terapeuttisesti käyttökelpoisten 5-etano-2,3,4,5-1H-2-bentsatsepin-7-olikarbamaattijohdannaisten valmistamiseksi
FI103881B1 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 5-fenyylisulfonyyliamino(karbonyyli)-pyridiini-2-karboksyylihappoestereiden valmistamiseksi
ATE66453T1 (de) Herstellung von zwischenverbindungen fuer leukotrien-antagonisten.
DE59203245D1 (de) Vorrichtung zur herstellung von glasmassechargen.
FR2679558B1 (fr) Procede de preparation de la cinnamoyl-13alpha baccatine iii ou desacetyl-10 baccatine iii.
FR2675345B1 (fr) Procede de fabrication d'un pave d'andouillette et pave d'andouillette ainsi obtenu.
FI964117A0 (fi) Menetelmä uusien 1-asyylipiperidiiniyhdisteiden valmistamiseksi
FI952957A0 (fi) Menetelmä aromaattisten amiiniyhdisteiden valmistamiseksi

Legal Events

Date Code Title Description
MM Patent lapsed